

Genotyping of the *Helicobacter pylori* *cagA* Gene Isolated From Gastric Biopsies in Shiraz, Southern Iran: A PCR-RFLP and Sequence Analysis Approach

Afsaneh Moaddeb,¹ Mohammad Reza Fattahi,² Roya Firouzi,¹ Abdollah Derakhshandeh,¹ and Shohreh Farshad^{3,*}

¹Department of Pathobiology, School of Veterinary Medicine, Shiraz University, Shiraz, IR Iran

²Gastroentorhepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran

³Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran

*Corresponding author: Shohreh Farshad, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, P. O. Box: 7193711351, Shiraz, IR Iran. Tel: +98-7136474304; +98-9173173501, Fax: +98-7136474303, E-mail: farshads@sums.ac.ir

Received 2015 May 26; Revised 2015 September 23; Accepted 2015 September 23.

Abstract

Background: Cytotoxin-associated gene A (*cagA*) is an important virulence factor in the pathogenesis of *Helicobacter pylori*.

Objectives: The aim of this study was to genotype the *H. pylori cagA* gene isolated from antral biopsies of patients with stomach symptoms, using a PCR-restriction fragment length polymorphism (PCR-RFLP) analysis.

Patients and Methods: A total of 161 gastric biopsies were collected from patients with stomach symptoms. After isolation of *H. pylori* from the biopsy culture, the *cagA* gene was assessed using PCR. The PCR products were then digested by the *HinfI* restriction endonuclease enzyme. A sample of each genotype was also subjected to direct sequencing for further analysis.

Results: From 161 antral biopsies, 61 (37.9%) were positive for *H. pylori* in culture. Overall, 24 *cagA*-positives were detected in the isolates. RFLP indicated three different genotypes (I, II, and III) of *cagA* with a frequency of 62.5%, 25%, and 12.5% among the isolates, respectively. Genotypes I and II of *cagA* were predominant in patients who had gastritis. However, genotype III was found in three patients with duodenitis and duodenal ulcers. Alignment of the nucleotide sequences of the three isolated genotypes, with *H. pylori* 26695 as a reference strain, revealed 12 inserted nucleotides in genotype III. When the sequence of genotype III was aligned with 15 additional *H. pylori* strains available in GenBank, the same inserted nucleotides were detected in six of them.

Conclusions: Using the PCR-RFLP method, three distinctive *H. pylori cagA* genotypes were detected in antral biopsies. Genotype I, which was predominant among the isolates, was significantly associated with gastritis. However, the data showed that *cagA* genotype III may play a role in duodenitis and duodenal ulcers in patients infected with *H. pylori*.

Keywords: Polymerase Chain Reaction, Restriction Fragment Length Polymorphism

1. Background

Helicobacter pylori, the most common pathogenic bacterium in the human stomach, is a microaerophilic, Gram-negative organism involved in peptic ulcer disease and gastric cancer (1). Many virulence factors are involved in the pathogenicity of *H. pylori*, including urease, vacuolating cytotoxin (a product of the *vacA* gene), and the immunogenic protein *CagA*, encoded by the *cytotoxin-associated gene A (cagA)*. While the *vacA* gene is present in all strains of *H. pylori*, *cagA* is not (2). The *cagA* gene is a virulence gene located in the *cag* pathogenicity island of the bacterial genome, and is frequently associated with more severe clinical outcomes (3-5). The *cagA* gene encodes proteins that increase the virulence potencies of strains, such as by increasing host-cell cytokine production and altering protein tyrosine phosphorylation (6, 7).

Many investigators have demonstrated that *H. pylori* pos-

sesses a remarkable degree of genetic diversity, closely related to its epidemiological and pathological characteristics and dynamics of transmission. Various methods have been employed for *H. pylori* genotyping, such as pulsed-field gel electrophoresis (PFGE), PCR-based randomly amplified polymorphic DNA (RAPD) fingerprinting, and hybridization with specific probes (8-10). By using restriction enzyme *EcoRI* and the PFGE method, a 97% improvement in *H. pylori* genotyping has been described (11). However, the PFGE method is time-consuming and requires a unique apparatus to handle a large number of clinical specimens. RAPD-PCR, on the other hand, has been reported to be a valuable method for the study of *H. pylori* genetic diversity and transmission (12). In comparison to PFGE, RAPD-PCR exhibits reasonable speed, cost, and efficiency. However, reproducibility is the main problem with this method. Recently, a novel peptide

nucleic acid probe for the specific detection of *H. pylori* in gastric biopsy specimens has been introduced (13). In this study, specific probes were used for the differentiation of *H. pylori* from other microorganisms. However, the sensitivity and specificity of this method were not compared with nucleic acid sequencing as a gold standard method.

PCR-RFLP analysis is another molecular method that has been used to investigate *H. pylori* genes, especially those that encode proteins in relation to bacterial pathogenicity, such as *cagA* and *vacA*, and urease structural and accessory proteins (14-18). However, the accuracy of the data provided by the PCR-RFLP method should be verified by a gold standard method when differentiating clinical isolates of *H. pylori*.

2. Objectives

In this study, we employed PCR-RFLP to investigate the genetic diversity of *cagA* as a virulence gene among *H. pylori* isolates recovered from antral biopsies of Iranian patients with stomach symptoms. The results were compared with nucleotide sequencing analysis as a gold standard method, to identify any changes in nucleotide sequences in *cagA*. The associations between the clinical status of the patients and the different genotypes were also investigated.

3. Patients and Methods

3.1. Patients

In this cross-sectional study, a total of 161 patients presenting to the endoscopy section at the Motahhary clinic, affiliated with Shiraz University of Medical Sciences (SUMS) in Shiraz, Iran, from July to December 2012, were enrolled in this study. Based on previous studies in the same area, the prevalence of *H. pylori* infection in patients with gastritis is 50% - 60%. Therefore, the sample size was derived with a 95% confidence interval and an estimate error of 7% - 8%. The calculated total sample size for the study was 160 gastric biopsy specimens. The patients had different gastric symptoms, such as stomach pain, nausea, dyspepsia, and gastritis. There were 61 males (37.9%) and 100 females (62.1%) in the study, with an age range of 16 - 80 years. The exclusion criteria were the use of antibiotics or proton pump inhibitors within two weeks prior to endoscopy, and previous gastric surgery. This study was approved by the ethical committee at SUMS, and all participants provided written informed consent.

3.2. Isolation and Identification of *Helicobacter pylori* Strains

Two antral biopsy samples were taken from each patient during endoscopic procedures for rapid urease test, gram staining and *H. pylori* culture for isolation and identification. The presence of urease produced by *H. pylori* was determined using modified rapid urease agar medium (19).

Briefly, one biopsy sample from each patient was inoculated into urea agar medium immediately after collection, and incubated at room temperature. A positive or negative reaction was determined on the basis of a change in color from yellow to red after a maximum period of two hours. Biopsy samples were also cultured on modified Columbia agar plates (Merck, Germany) containing 10% lysed horse blood, and incubated under microaerobic conditions in an anaerobic jar at 37°C for 2 - 3 days, as previously described (20). The organisms were identified as *H. pylori* by colony morphology, gram staining, and positive oxidase, catalase, and urease tests. Positive cultures were harvested and stored in sterile distilled water at -70°C for further investigations.

3.3. DNA Extraction

The genomic DNA of the *H. pylori* isolates was obtained using the boiling extraction method. Briefly, 300 µL of thawed isolated *H. pylori* samples were incubated at 95°C for 10 minutes. The samples were then centrifuged at 14,000 g for 10 minutes and the supernatants were stored at -20°C until being used as PCR templates. DNA concentration was assessed by spectrophotometry (NanoDrop ND-1000, USA).

3.4. Detection of *H. pylori* and *cagA* Gene by PCR

To confirm *H. pylori* species, a set of published primers was used to amplify the 294 bp fragment of the *glmM* gene, which encodes phosphoglucosamine mutase (21). PCR was performed in a total volume of 25 µL containing 10 ng of genomic DNA from the *H. pylori* culture, 200 µM of dNTP, 1.5 mM of MgCl₂, 0.5 µM of each primer, and 1.25 U of Taq polymerase. The PCR condition for amplification was performed with a one-cycle initial denaturation step at 93°C for 5 minutes, followed by 35 cycles at 93°C for one minute, 55°C for one minute, and 72°C for one minute. A final extension was performed at 72°C for five minutes.

To detect the presence of the *cagA* gene, primer *cagA* F [5'-AGT AAG GAG AAA CAA TGA-3'] and primer *cagA* R [5'-AAT AAG CCT TAG AGT CTT TTT GGA AAT C-3'] were used to amplify a 1320-bp band of the target gene (18). The PCR mixture consisted of 200 µM of dNTPs, 1.5 mM of MgCl₂, 0.5 µM of each primer, 1.25 U of Taq DNA polymerase, and 20 ng of DNA template in a 50 µL final volume. Negative and positive controls were also included in the PCR assay. Thermal cycling was set at a one-cycle initial denaturation at 94°C for 2 minutes, 35 cycles of 45 seconds for denaturation at 94°C, 45 seconds for annealing at 50°C, and 45 seconds for extension at 72°C, with a final extension at 72°C for 5 minutes.

The PCR products were electrophoresed on agarose gel, and amplified DNA was stained with ethidium bromide and observed under gel documentation (UVitec, England). A 100-bp DNA ladder was used as a molecular size marker.

3.5. RFLP Assay

The *cagA* gene amplicons were digested by HinfI as an endonuclease enzyme, according to the manufacturer's

instructions. The site recognized by this enzyme is 5' G*AN T C 3'. For this purpose, 10 µL of each PCR product of the *cagA* gene was mixed with 1 U of *HinfI* restriction enzyme (Fermentase, Fermentas, Lithuania) and 1 µL of 10X restriction buffer, then incubated at 37°C for 3 hours. The digested products were then electrophoresed on 2% agarose gel, stained with ethidium bromide, and observed under gel documentation (UVitec, England). A 100-bp DNA ladder was used as a marker for molecular size.

3.6. Sequencing of *cagA* Products

After RFLP analysis, one strain of each genotype of *cagA* PCR product was randomly selected and sequenced. For sequencing, the *cagA* PCR products were first purified with a column-based purification kit (Millipore), then sequenced by the Sanger method using an ABI 3730XL instrument (Sequetech Corp. CA, USA). The recognition sites of the *HinfI* enzyme within the sequence region were analyzed with the Serial Cloner V2.5 program.

3.7. Sequence Analysis of *cagA* PCR Products

The sequenced *cagA* genotypes were aligned with GenBank accession number AE000511 (corresponding to nucleotides 579907 - 581241 of *H. pylori* 26695) as a reference. The homology of the DNA sequences to the published sequences was determined by using the BLAST window on the National center for biotechnology information (NCBI) website (<http://www.ncbi.nlm.nih.gov/BLAST/>).

Three sequenced genotypes (KJ728721.1, genotype I; KJ728722.1, genotype II; and KJ728723.1, genotype III) were aligned with 15 sequences available in the GenBank database, using the CLUSTAL W method (accession numbers: AE000511.1, 26695; AE001439.1, J99; JQ685154.1, J166 USA; CP002983.1, SNT49 USA; FR666835.1, USA; FR666825.1, UK; CP002332.1, Gambia; CP002334.1, Lithuania; GQ161099.1, China; DQ306710.1, China; AY884089.1, Korea; AB190951.1, Japan; DQ091000.1, Japan; AF202973.1, Japan; and FJ79854.1, Vietnam).

The phylogenetic analysis was performed using Mega 4 software (Beta MacOSX version) following the recommended instructions. The phylogenetic tree was constructed via the neighbor-joining method following 500 bootstrap surveys.

3.8. Statistical Analysis

Statistical analysis of the data was performed with Fisher's exact test using SPSS version 17.0 (Chicago, IL, USA) for Windows, and a P-value of less than 0.05 was considered significant.

4. Results

4.1. Isolation of *Helicobacter pylori* From Biopsy Specimens

Overall, 61 out of 161 antral biopsy specimens were positive for *H. pylori* according to the rapid urease test and cul-

ture. All of the isolates were confirmed by the *glmM* gene PCR assay, as well. With regard to the endoscopic examinations, there were diagnoses of gastritis (n = 47, 77%), duodenitis (n = 7, 11.5%), and duodenal ulcers (n = 7, 11.5%).

4.2. PCR Amplification and Restriction Fragment Length Polymorphism Analysis of the *cagA* Gene

Using a specific primer, a 1320-bp fragment of the *cagA* gene was detected in 24 out of 61 isolates (39.3%). Of those, 17 isolates belonged to patients with gastritis (70.9%), two were in patients with duodenitis (8.3%), and five were in patients with duodenal ulcers (20.8%). The distributions of *H. pylori cagA*-negative strains isolated from patients with gastritis, duodenitis, and duodenal ulcers were, respectively, n = 30, 81.1%; n = 5, 13.5%; and n = 2, 5.4%. When the RFLP analysis was performed on the 24 *cagA*-positive isolates using *HinfI* restriction endonuclease, three different genotypes of *cagA* were determined on agarose gel electrophoresis (Figure 1).

Genotypes I and II had three distinct DNA fragments with different sizes. Genotype III, on the other hand, revealed four DNA fragments on agarose gel electrophoresis. Among all of the *H. pylori cagA*-positive isolates, the prevalence of genotype I was significantly higher than the other two genotypes, at 62.5% versus 25% and 12%, respectively (P = 0.014). The associations of each of the *cagA* genotypes with the gastroduodenal diseases are shown in Table 1.

4.3. Sequence Analysis of *cagA* PCR Products and BLAST Query

Table 2 indicates the identities of *cagA* gene nucleotides, determined by PCR direct sequencing, and the deduced amino acid sequences among three *H. pylori* isolates and *H. pylori* 26695, using the NCBI protein BLAST query.

4.4. Submission of Three Genotypes to the NCBI Database

Three sequenced *cagA* genotypes were submitted to the NCBI database. Of the three *cagA*-positive *H. pylori* strains, two were from non-ulcer disease (NUD) patients with gastritis (GenBank accession numbers KJ728721 and KJ728722), and one was from a duodenal ulcer (DU) patient (GenBank accession number KJ728723).

4.5. PCR Product Sequence Analysis of Three *cagA* Genotypes

Each of the sequenced *cagA* genotypes were entered into the serial cloner V2.5 program, which revealed the actual fragment size digested by the *HinfI* restriction enzyme (Table 3).

4.6. Analysis of PCR Product Sequences of Three *cagA* Genotypes in Comparison With the *Helicobacter pylori* Reference Gene


The nucleotide sequences of three *cagA* genotypes were compared to nucleotides 579907 - 581241 of *H. pylori* 26695, which indicated that there were some base-substitution events within the *cagA* gene of the strains isolated from the patients. Some of these changed the sequence bases to the non-cut sites of *HinfI*; therefore, three genotypes (I, II, and III) of *cagA* were detected among the isolates. In genotype II, there was a base substitution of G1193A that provided a region not cut by *HinfI*. Interestingly, in genotype III, the base substitutions of G₂₀₈A, AA₃₃₇₋₈GT, C₅₃₉T, G₅₄₈A, T551C, and G₁₂₁₉A induced non-cutting sites by *HinfI*. On the other hand, the base substitutions of GA₃₆₉₋₇₀AC and G₈₀₁T induced new cutting sites by the enzyme. No insertions or deletions were found within the *cagA* region in genotypes I and II. However, two base deletions and 14 base insertions were detected in genotype III. The deduced amino acid sequences could be determined without a stop codon, and there were also some differences in the nucleotides and the amino acid sequences among the three *cagA* genotypes.

Alignment of the nucleotide sequences of the three isolated genotypes, with *H. pylori* 26695 as a reference strain, revealed that in genotype III (KJ728723.1), 12 nucleotides had been inserted (GAG AGC CTA CTG) in positions nt 626 - 637. When the sequence of genotype III was aligned with 15 additional *H. pylori* strains available in the GenBank database, the same sequences were detected among six strains with the following accession numbers: GQ161099.1, China; AE001439.1, J99; FR666825.1, UK; JQ685154.1, J166 USA;

AY884089.1, Korea; and AB190951.1, Japan.

The phylogenetic analysis revealed a sequence disparity among the three isolated genotypes, as depicted in Figure 2. This result demonstrated that two isolates in this study (genotype I = KJ728721.1, genotype II = KJ72871.1) had the same diversity, as they were located close together in the same branch. Another isolate (genotype III = KJ728723.1) showed a different phylogenetic pattern, as it moved to another taxa on a completely separate branch.

Figure 1. RFLP of the 1320-bp DNA Fragment of the *Helicobacter pylori cagA* Gene Isolated From Biopsy Specimens Using the *HinfI* Restriction Enzyme



Lanes 1, 3, 7, 9, and 16, genotype I; lanes 2, 4, 6, 8, 10, 15, 17, and 19, *cagA* gene without *HinfI* restriction enzyme; lane 5, genotype III; lane 11, DNA ladder (100 bp); lanes 18 and 20, genotype II.

Table 1. Associations of *Helicobacter pylori cagA* Genotypes With Gastroduodenal Diseases^a

<i>cagA</i> Genotypes	No. of Isolates From Gastroduodenal Disease			Total
	Gastritis	Duodenitis	Duodenal Ulcer	
I	12 (70.6) ^b	0 (0)	3 (60)	15 (62.5)
II	5 (29.4)	0 (0)	1 (20)	6 (25)
III	0 (0)	2 (100)	1 (20)	3 (12.5)
Total	17	2	5	24

^aValues are expressed as No (%).
^bP = 0.014.

Table 2. Identities of Nucleotides and Deduced Amino Acid Sequences Determined by PCR Direct Sequencing Among Three *cagA* Genotypes and *Helicobacter pylori* 26695^a

Comparison of Strains	Identity of Nucleotide Sequence	Identity of Amino Acid Sequence
I with <i>H. pylori</i> 26695	1293/1335 (97)	420/440 (95)
II with <i>H. pylori</i> 26695	1302/1335 (98)	428/440 (97)
III with <i>H. pylori</i> 26695	1231/1349 (91)	388/444 (87)
I with II	1297/1335 (97)	424/440 (96)
I with III	1211/1349 (90)	378/444 (85)
II with III	1226/1349 (91)	387/444 (87)

^aThe values are expressed as No (%).

Table 3. Sequence Analysis of Three *cagA* Genotypes Using *HinfI* Restriction Enzyme and the Serial Cloner Program^a

Strain Group	Fragment Length	Sum
Reference strain <i>H. pylori</i> 26695	274, 249, 208, 199, 127, 70, 58, 43, 43, 36, 15, and 13	1335
Genotype I	273, 249, 208, 199, 127, 70, 58, 43, 43, 36, 15, and 13	1335
Genotype II	376, 274, 208, 199, 70, 58, 43, 43, 36, 15, and 13	1335
Genotype III	375, 266, 223, 207, 102, 79, 43, 36, and 15	1347

^aThe values' unit is bp.




Figure 2. Phylogenetic Tree of Isolates Based on *cagA* Nucleotide Sequences

5. Discussion

In the present study, we employed PCR-RFLP to investigate the genotypes of the *cagA* gene in *H. pylori* strains isolated from antral biopsies of patients with stomach symptoms. The *cagA* gene was detected in 39.3% of *H. pylori*-positive isolates. However, no significant association was found between the presence of the *cagA* gene and upper gastrointestinal disorders in the patients infected with *H. pylori*. Based on different geographical regions, the prevalence of *cagA*-positive strains among the Iranian population is between 35% and 94% (22-25). In a previous study in Shiraz, 47.7% of *H. pylori* isolates were *cagA*-positive, which was higher in patients with UD than in those with NUD. However, no significant difference was detected in the prevalence of the *cagA* gene between the two groups (22). The variability of *cagA* status might be due to the different PCR primer sets used in different studies. There may be several distinct forms of the *cagA* gene, with an uneven geographical distribution. Such differences in *cagA* genotypes can serve as markers for differences in virulence among *cagA*-positive strains.

Using the *HinfI* restriction enzyme, PCR-RFLP revealed three distinct genotypes of *cagA* among the *H. pylori* strains according to base size and number of bands (fragments) in agarose gel, which confirmed that there is genetic diversity in the *cagA* gene of the isolates. Genotypes I and II of *cagA* were predominant in patients who had gastritis, while genotype III was found in three patients with duodenitis and duodenal ulcers. In a previous study using the same restriction enzyme, two genotypes, α (no cut) and β (3 bands), with no significant association with a specific clinical outcome, were identified (18). Since the PCR products were not sequenced in that study, it is not obvious whether genotype β is identical to genotypes I or II in our study.

Takamura et al. (26) employed PCR-RFLP for genotyping the *H. pylori cagA* gene isolated from paraffin-embedded sections of gastric cancer. The study populations were Brazilian and Japanese patients. Analysis of PCR-RFLP for the *cagA* gene showed that the prevalence of the east Asia subtype was significantly higher in the Japanese subjects than in the Brazilians (26), and the authors concluded that this genotype contributes to the progression of gastritis in the region.

In general, the PCR-RFLP method is a useful tool for genotyping the *H. pylori cagA* gene among clinical isolates. However, this method is limited to the detection of mutations only at the restriction sites of the enzymes, even if many other regions differ throughout the complete genome. The PCR direct sequencing method has been applied in the typing of *H. pylori* clinical isolates (27, 28). This method can provide a tool for analyzing the nucleotide alignment within a gene; therefore, it has some advantages over other methods that analyze only restriction-site changes in a single gene, such as PFGE and PCR-RFLP.

The results of the RFLP analysis resolved by agarose gel electrophoresis were nearly identical to the predicted fragments, based on the nucleotide sequence data. However, the DNA fragments below 70 bp, as predicted from the nucleotide sequence, were too small to be seen on agarose gel. Since the agarose gel we used in this study was not able to discriminate between DNA fragments with a few nucleotides of different sizes, fragment overlap was likely.

Analysis of the nucleotide sequences indicated that there were some base-substitution events within the *cagA* gene of the strains isolated from the patients. Some changed the sequence bases to the non-cut sites of *HinfI*,

and vice versa. Therefore, three genotypes (I, II, and III) of *cagA* were detected among the isolates. Some base substitutions, insertions, or deletions induced new amino acid sequences throughout the *cagA* gene; for instance, substitution of the codon GAA with GGT in nucleotide positions 337 and 338 changed negatively-charged glutamic acid into neutral glycine. Since the majority of the nucleotide alterations occurred in genotype III, it is possible that the severity of disease caused by this genotype is attributed to mutations in the nucleotides. On the other hand, variation in some nucleotides affected the *HinfI* activity and induced non-cutting sites on the sequence.

Alignment of the three sequenced genotypes of *H. pylori cagA* PCR products in our study with different *H. pylori cagA* genotypes, which were submitted to the NCBI GenBank database, revealed 12 inserted nucleotides (GAG AGC CTA CTG) in positions nt 626 – 637 in genotype III. Six of the aforementioned sequences were translated to glycine, glutamic acid, proline, and threonine (GEPT) amino acids in positions aa 209 – 212. GEPT amino acids are located in the amino-terminal domain (DI; aa 24 – 221) of *cagA*, which activates inflammatory responses via NFκB and prevents apoptosis via the tumor suppressor p53, and this may impact the severity of disease (29).

The phylogenetic analysis revealed that compared to genotype III, the isolated genotypes I and II had much greater similarity to *H. pylori* SNT49 USA, *H. pylori* Gambia, and *H. pylori* 26695. On the other hand, genotype III was much more similar to *H. pylori* J99 Lithuania, *H. pylori* Korea, and *H. pylori* UK. These data indicate that there is diversity among *cagA H. pylori* strains isolated from different geographical regions, which may impact the severity of disease.

In conclusion, three distinctive *H. pylori cagA* genotypes were detected in antral biopsies, using the PCR-RFLP method. Genotype I, which was predominant among the isolates, was significantly associated with gastritis. However, the inserted nucleotides in *cagA* genotype III, which were revealed by the nucleotide sequencing analysis, may play a role in duodenitis and duodenal ulcers in patients infected with *H. pylori*. To support the data, more clinical samples from patients with different gastrointestinal symptoms and from different geographic regions need to be tested. Sequencing and comparisons of complete *cagA* genes isolated from different geographic regions is also recommended.

Acknowledgments

This study was developed from the PhD dissertation of Afsaneh Moaddeb and supported by a research grant from Shiraz University, Shiraz, Iran, and the clinical microbiology research center, Shiraz University of Medical Sciences, Shiraz, Iran (grant number 90/9). The authors wish to thank the staff of the endoscopy unit in Nemazee hospital for their assistance in specimen collection, and deep gratitude goes to Dr. Hassan Khajehei for copy-editing our manuscript.

Footnote

Authors' Contribution: Afsaneh Moaddeb: developed the study from PhD dissertation, carried out the laboratory and molecular experiments, analyzed the data, interpreted the results, and wrote the manuscript; Mohammad Reza Fattahi: as a specialist, carried out endoscopies and took antral biopsy specimens from the patients; Roya Firouzi: study concept and design, critical revision of the manuscript for important intellectual content, and study supervision; Abdollah Derakhshandeh: molecular approaches; Shohreh Farshad: study concept and design, critical revision of the manuscript for important intellectual content, and study supervision.

References

- Blaser MJ. Hypothesis: the changing relationships of *Helicobacter pylori* and humans: implications for health and disease. *J Infect Dis.* 1999;**179**(6):1523-30. doi: 10.1086/314785. [PubMed: 10228075]
- Suerbaum S, Michetti P. *Helicobacter pylori* infection. *N Engl J Med.* 2002;**347**(15):1175-86. doi: 10.1056/NEJMra020542. [PubMed: 12374879]
- Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, et al. *cagA*, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific and disease-associated virulence factors. *Proc Natl Acad Sci U S A.* 1996;**93**(25):14648-53. [PubMed: 8962108]
- Palli D, Masala G, Del Giudice G, Plebani M, Basso D, Berti D, et al. *CagA+* *Helicobacter pylori* infection and gastric cancer risk in the EPIC-EURGAST study. *Int J Cancer.* 2007;**120**(4):859-67. doi: 10.1002/ijc.22435. [PubMed: 17131317]
- Jones KR, Joo YM, Jang S, Yoo YJ, Lee HS, Chung IS, et al. Polymorphism in the *CagA* EPIYA motif impacts development of gastric cancer. *J Clin Microbiol.* 2009;**47**(4):959-68. doi: 10.1128/JCM.02330-08. [PubMed: 19158258]
- Ando T, Perez-Perez GI, Kusugami K, Ohsuga M, Bloch KC, Blaser MJ. Anti-*CagA* immunoglobulin G responses correlate with interleukin-8 induction in human gastric mucosal biopsy culture. *Clin Diagn Lab Immunol.* 2000;**7**(5):803-9. [PubMed: 10973458]
- Odenbreit S, Puls J, Sedlmaier B, Gerland E, Fischer W, Haas R. Translocation of *Helicobacter pylori CagA* into gastric epithelial cells by type IV secretion. *Science.* 2000;**287**(5457):1497-500. [PubMed: 10688800]
- Fantry GT, Zheng QX, Darwin PE, Rosenstein AH, James SP. Mixed infection with *cagA*-positive and *cagA*-negative strains of *Helicobacter pylori*. *Helicobacter.* 1996;**1**(2):98-106. [PubMed: 9398886]
- Prewett EJ, Bickley J, Owen RJ, Pounder RE. DNA patterns of *Helicobacter pylori* isolated from gastric antrum, body, and duodenum. *Gastroenterology.* 1992;**102**(3):829-33. [PubMed: 1347029]
- Pina M, Occhialini A, Monteiro L, Doermann HP, Megraud F. Detection of point mutations associated with resistance of *Helicobacter pylori* to clarithromycin by hybridization in liquid phase. *J Clin Microbiol.* 1998;**36**(11):3285-90. [PubMed: 9774580]
- Hosaka Y, Irinoda K, Nakano R, Tanabe S, Koizumi W, Saigenji K, et al. Use of the restriction enzyme *EcoRI* for pulsed-field gel electrophoretic analysis of *Helicobacter pylori*. *J Clin Microbiol.* 2005;**43**(2):931-2. doi: 10.1128/JCM.43.2.931-932.2005. [PubMed: 15695710]
- Soto G, Bautista CT, Roth DE, Gilman RH, Velapatino B, Ogura M, et al. *Helicobacter pylori* reinfection is common in Peruvian adults after antibiotic eradication therapy. *J Infect Dis.* 2003;**188**(9):1263-75. doi: 10.1086/379046. [PubMed: 14593583]
- Guimaraes N, Azevedo NF, Figueiredo C, Keevil CW, Vieira MJ. Development and application of a novel peptide nucleic acid probe for the specific detection of *Helicobacter pylori* in gastric biopsy specimens. *J Clin Microbiol.* 2007;**45**(9):3089-94. doi: 10.1128/JCM.00858-07. [PubMed: 17609326]

14. Shortridge VD, Stone GG, Flamm RK, Beyer J, Versalovic J, Graham DW, et al. Molecular typing of *Helicobacter pylori* isolates from a multicenter U.S. clinical trial by ureC restriction fragment length polymorphism. *J Clin Microbiol*. 1997;**35**(2):471-3. [PubMed: 9003618]
15. Han SR, Schreiber HJ, Bhakdi S, Loos M, Maeurer MJ. vacA genotypes and genetic diversity in clinical isolates of *Helicobacter pylori*. *Clin Diagn Lab Immunol*. 1998;**5**(2):139-45. [PubMed: 9521135]
16. Owen RJ, Slater ER, Xerry J, Peters TM, Teare EL, Grant A. Development of a scheme for genotyping *Helicobacter pylori* based on allelic variation in urease subunit genes. *J Clin Microbiol*. 1998;**36**(12):3710-2. [PubMed: 9817904]
17. Tanahashi T, Kita M, Kodama T, Sawai N, Yamaoka Y, Mitsufoji S, et al. Comparison of PCR-restriction fragment length polymorphism analysis and PCR-direct sequencing methods for differentiating *Helicobacter pylori* ureB gene variants. *J Clin Microbiol*. 2000;**38**(1):165-9. [PubMed: 10618081]
18. Farshad S, Japoni A, Alborzi A, Hosseini M. Restriction fragment length polymorphism of virulence genes cagA, vacA and ureAB of *Helicobacter pylori* strains isolated from Iranian patients with gastric ulcer and nonulcer disease. *Saudi Med J*. 2007;**28**(4):529-34. [PubMed: 17457472]
19. Shahidi MA, Fattahi MR, Farshad S, Alborzi A. Validation of an in-house made rapid urease test kit against the commercial CLO-test in detecting *Helicobacter pylori* infection in the patients with gastric disorders. *J Res Med Sci*. 2012;**17**(3):212-6. [PubMed: 23267370]
20. Farshad S, Japoni A, Shahidi MA, Hosseini M, Alborzi A. An improvement in isolation and preservation of clinical strains of *Helicobacter pylori*. *Trop Gastroenterol*. 2011;**32**(1):36-40. [PubMed: 21922854]
21. Lu JJ, Perng CL, Shyu RY, Chen CH, Lou Q, Chong SK, et al. Comparison of five PCR methods for detection of *Helicobacter pylori* DNA in gastric tissues. *J Clin Microbiol*. 1999;**37**(3):772-4. [PubMed: 9986850]
22. Farshad S, Alborzi A, Abbasian A. Association of *H. pylori* virulence genes CagA, VacA and UreAB with ulcer and nonulcer diseases in Iranian population. *Pak J Biol Sci*. 2007;**10**(8):1185-9. [PubMed: 19069914]
23. Momtaz H, Souod N, Dabiri H, Sarshar M. Study of *Helicobacter pylori* genotype status in saliva, dental plaques, stool and gastric biopsy samples. *World J Gastroenterol*. 2012;**18**(17):2105-11. doi: 10.3748/wjg.v18.i17.2105. [PubMed: 22563199]
24. Latifi-Navid S, Mohammadi S, Maleki P, Zahri S, Yazdanbod A, Siavoshi F, et al. *Helicobacter pylori* vacA d1/i1 genotypes and geographic differentiation between high and low incidence areas of gastric cancer in Iran. *Arch Iran Med*. 2013;**16**(6):330-7. [PubMed: 23725065]
25. Teymournejad O, Shokoohizadeh L, Mohabati Mobarez A, Amini M. *Helicobacter Pylori* and CagA: Relationships With Esophageal and Gastrointestinal Disorders in Iranian Patients. *Int J Enteric Pathog*. 2015;**3**(2):e25022. doi:10.17795/ijep25022.
26. Takamura A, Ito M, Imagawa S, Takata S, Tanaka S, Teixeira CR, et al. *Helicobacter pylori* cagA polymorphism and gastric inflammation: an international comparison between Japanese and Brazilian patients. *Scand J Gastroenterol*. 2011;**46**(9):1051-6. doi: 10.3109/00365521.2011.598549. [PubMed: 21736532]
27. Ito Y, Azuma T, Ito S, Suto H, Miyaji H, Yamazaki Y, et al. Full-length sequence analysis of the vacA gene from cytotoxic and noncytotoxic *Helicobacter pylori*. *J Infect Dis*. 1998;**178**(5):1391-8. [PubMed: 9780260]
28. van der Ende A, Pan ZJ, Bart A, van der Hulst RW, Feller M, Xiao SD, et al. cagA-positive *Helicobacter pylori* populations in China and The Netherlands are distinct. *Infect Immun*. 1998;**66**(5):1822-6. [PubMed: 9573056]
29. Yamaoka Y. Mechanisms of disease: *Helicobacter pylori* virulence factors. *Nat Rev Gastroenterol Hepatol*. 2010;**7**(11):629-41. doi: 10.1038/nrgastro.2010.154. [PubMed: 20938460]